GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embla Medical hf (OCSE:EMBLA) » Definitions » Research & Development

Embla Medical hf (OCSE:EMBLA) Research & Development : kr263 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Embla Medical hf Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Embla Medical hf's Research & Development for the three months ended in Mar. 2024 was kr68 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was kr263 Mil.

Embla Medical hf Research & Development Historical Data

The historical data trend for Embla Medical hf's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embla Medical hf Research & Development Chart

Embla Medical hf Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 210.60 189.69 208.85 238.95 260.69

Embla Medical hf Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.67 64.69 62.08 69.10 67.56

Embla Medical hf Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr263 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embla Medical hf  (OCSE:EMBLA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Embla Medical hf Research & Development Related Terms

Thank you for viewing the detailed overview of Embla Medical hf's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Embla Medical hf (OCSE:EMBLA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embla Medical hf (OCSE:EMBLA) » Definitions » Research & Development
Comparable Companies
OCSE:CHEMM OCSE:GN OCSE:SMSMED OCSE:VIRO OCSE:AMBU B TSE:5212 ABT SYK MDT BSX EW DXCM SZSE:300760 ZBH ALGN STE XAMS:PHIA XSWX:SOON SHSE:688271 ASX:COH
Traded in Other Exchanges
OSSFF:USA OSSUY:USA
Address
Grjothals 5, Reykjavik, ISL
Website
https://www.ossur.com
Ossur hf is engaged in the design, development, manufacture, and sale of prosthetics and bracing & support products. The company's products improve mobility through technologies in the field of braces, supports, prosthetic limbs, and compression therapy. Its segments are the Bracing & Supports and Prosthetics segment. The bracing & support products are used to support joints and other body parts for therapeutic and preventative purposes. The Prosthetics segment includes artificial limbs and related products for individuals born without limbs. Its geographical segments are the Americas; Europe, the Middle East & Africa (EMEA); and the Americas & Asia-Pacific (APAC), of which the Americas generate nearly half of the company's revenue.

Embla Medical hf (OCSE:EMBLA) Headlines

No Headlines